96 related articles for article (PubMed ID: 20144594)
1. Factors determining sensitivity or resistance of tumor cell lines towards artesunate.
Sertel S; Eichhorn T; Sieber S; Sauer A; Weiss J; Plinkert PK; Efferth T
Chem Biol Interact; 2010 Apr; 185(1):42-52. PubMed ID: 20144594
[TBL] [Abstract][Full Text] [Related]
2. Molecular modes of action of artesunate in tumor cell lines.
Efferth T; Sauerbrey A; Olbrich A; Gebhart E; Rauch P; Weber HO; Hengstler JG; Halatsch ME; Volm M; Tew KD; Ross DD; Funk JO
Mol Pharmacol; 2003 Aug; 64(2):382-94. PubMed ID: 12869643
[TBL] [Abstract][Full Text] [Related]
3. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.
Efferth T; Volm M
In Vivo; 2005; 19(1):225-32. PubMed ID: 15796179
[TBL] [Abstract][Full Text] [Related]
4. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins.
Anfosso L; Efferth T; Albini A; Pfeffer U
Pharmacogenomics J; 2006; 6(4):269-78. PubMed ID: 16432535
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells.
Youns M; Efferth T; Reichling J; Fellenberg K; Bauer A; Hoheisel JD
Biochem Pharmacol; 2009 Aug; 78(3):273-83. PubMed ID: 19393226
[TBL] [Abstract][Full Text] [Related]
6. Role of antioxidant genes for the activity of artesunate against tumor cells.
Efferth T; Briehl MM; Tome ME
Int J Oncol; 2003 Oct; 23(4):1231-5. PubMed ID: 12964009
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines.
Sertel S; Eichhorn T; Simon CH; Plinkert PK; Johnson SW; Efferth T
Molecules; 2010 Apr; 15(4):2886-910. PubMed ID: 20428086
[TBL] [Abstract][Full Text] [Related]
8. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
9. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells.
Efferth T; Giaisi M; Merling A; Krammer PH; Li-Weber M
PLoS One; 2007 Aug; 2(8):e693. PubMed ID: 17668070
[TBL] [Abstract][Full Text] [Related]
10. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
[TBL] [Abstract][Full Text] [Related]
11. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
12. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
13. Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas.
Simon M; Voss D; Park-Simon TW; Mahlberg R; Köster G
Oncol Rep; 2006 Jul; 16(1):127-32. PubMed ID: 16786135
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.
Efferth T; Ramirez T; Gebhart E; Halatsch ME
Biochem Pharmacol; 2004 May; 67(9):1689-700. PubMed ID: 15081868
[TBL] [Abstract][Full Text] [Related]
15. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
16. Microarray-based expression of DNA repair genes does not correlate with growth inhibition of cancer cells by natural products derived from traditional Chinese medicine.
Konkimalla VS; Wang G; Kaina B; Efferth T
Cancer Genomics Proteomics; 2008; 5(2):79-84. PubMed ID: 18460736
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of Cameroonian traditional herbal medicine for cancer therapy.
Kuete V; Efferth T
J Ethnopharmacol; 2011 Sep; 137(1):752-66. PubMed ID: 21763411
[TBL] [Abstract][Full Text] [Related]
18. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
Andrews P; Zhao X; Allen J; Li F; Chang M
Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
[TBL] [Abstract][Full Text] [Related]
20. Potential role of transforming growth factor beta1 in drug resistance of tumor cells.
Stoika R; Yakymovych M; Souchelnytskyi S; Yakymovych I
Acta Biochim Pol; 2003; 50(2):497-508. PubMed ID: 12833174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
